Mirabella Financial Services LLP Makes New Investment in Standard BioTools Inc. (NASDAQ:LAB)

Mirabella Financial Services LLP acquired a new stake in shares of Standard BioTools Inc. (NASDAQ:LAB) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 3,130,190 shares of the company’s stock, valued at approximately $5,478,000. Mirabella Financial Services LLP owned approximately 0.84% of Standard BioTools as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. State Street Corp boosted its stake in Standard BioTools by 26.7% during the third quarter. State Street Corp now owns 5,495,136 shares of the company’s stock worth $10,606,000 after acquiring an additional 1,157,984 shares in the last quarter. Barclays PLC lifted its holdings in shares of Standard BioTools by 13.2% during the third quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock valued at $6,231,000 after purchasing an additional 377,195 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Standard BioTools by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 6,949,717 shares of the company’s stock worth $13,415,000 after purchasing an additional 154,848 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Standard BioTools by 7.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock worth $270,000 after buying an additional 9,995 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in Standard BioTools by 34.2% during the 4th quarter. SG Americas Securities LLC now owns 135,927 shares of the company’s stock valued at $238,000 after buying an additional 34,670 shares in the last quarter. Institutional investors own 53.74% of the company’s stock.

Insider Buying and Selling

In related news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the stock in a transaction dated Friday, February 28th. The shares were purchased at an average price of $1.06 per share, with a total value of $5,110,216.54. Following the completion of the acquisition, the director now owns 58,846,780 shares of the company’s stock, valued at $62,377,586.80. This represents a 8.92 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 53.10% of the stock is currently owned by insiders.

Standard BioTools Stock Up 2.7 %

Standard BioTools stock opened at $1.16 on Friday. The company has a market cap of $439.62 million, a P/E ratio of -1.63 and a beta of 1.54. The business has a 50-day simple moving average of $1.17 and a two-hundred day simple moving average of $1.58. Standard BioTools Inc. has a 52-week low of $0.97 and a 52-week high of $2.74.

Analyst Upgrades and Downgrades

Separately, KeyCorp downgraded shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a research report on Thursday, February 27th.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.